Pharmexa prevails in opposition to Geron's European patent

By Lisa Kerner

Charlotte, N.C., June 14 - Pharmexa A/S said the European Patent Office has granted its request to invalidate three claims related to peptide vaccines in Geron's European telomerase patent.

Geron has the option to appeal the decision. The company filed a similar opposition against Pharmexa's European patent leading to modified claims by Pharmexa.

Based in Denmark, Pharmexa is focused on active immunotherapy and vaccines for the treatment of cancer, serious chronic diseases and infectious diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.